PT  - JOURNAL ARTICLE
AU  - Suzanne M Cadarette
AU  - Jeffrey N Katz
AU  - M Alan Brookhart
AU  - Raisa Levin
AU  - Margaret R Stedman
AU  - Niteesh K Choudhry
AU  - Daniel H Solomon
TI  - Trends in drug prescribing for osteoporosis after hip fracture, 1995-2004.
DP  - 2008 Feb 01
TA  - The Journal of Rheumatology
PG  - 319--326
VI  - 35
IP  - 2
4099  - http://www.jrheum.org/content/35/2/319.short
4100  - http://www.jrheum.org/content/35/2/319.full
SO  - J Rheumatol2008 Feb 01; 35
AB  - OBJECTIVE: To examine trends in osteoporosis drug prescribing after hip fracture from 1995 to 2004. METHODS: We conducted a population-based study of enrollees in the Pennsylvania Pharmaceutical Assistance Contract for the Elderly. Hip fractures were identified using Medicare hospital claims between January 1, 1995, and June 30, 2004. Osteoporosis treatment comprised oral bisphosphonates, calcitonin, hormone therapy, raloxifene, and/or teriparatide. Kaplan-Meier methods were used to estimate the probability of treatment within 6 months of fracture, censoring patients on their date of death or 6 months postfracture. RESULTS: Treatment within 6 months after hip fracture improved from 7% in 1995 to 31% in 2002, and then remained stable through 2004. Similar patterns were observed among new users, with treatment increasing from 4% in 1995 to 17% in 2002, with no subsequent increase through 2004. Bisphosphonates led other treatments in the frequency of prescribing, except during 1997-99, when calcitonin was the most common. Among women, hormone therapy prescribing decreased from 22% of those treated in 1995 to 4% in 2004, and raloxifene prescribing remained relatively constant (4%-10%) since its introduction (p for trend = 0.15). Of patients treated before and after hip fracture, 18% changed therapy postfracture. Significantly more patients changed therapy following fracture if a different physician prescribed treatment (26%) compared to those treated by the same physician pre- and postfracture (13%; p < 0.0001). CONCLUSION: Prescribing practices changed substantially over the 10 years of study. The proportion of hip fracture patients treated with osteoporosis drugs has increased, but remains low, with fewer than one-third receiving pharmacotherapy.